Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
CLNNClene(CLNN) Newsfilter·2024-04-17 04:01

Clene Inc.和Clene Nanomedicine, Inc.在AAN年会上展示Phase 2 VISIONARY-MS LTE研究结果 - CNM-Au8治疗在患有多发性硬化症（MS）的患者中显示出修复和重髓鞘效应的证据[3] - CNM-Au8治疗导致了多个临床和临床外端点的显著改善，包括认知和视觉功能[5] - CNM-Au8治疗对神经元功能和重髓鞘的生理和结构证据显示出显著改善[8][9] - CNM-Au8治疗在三年的辅助治疗中持续改善多个临床和临床外端点，为进行第三阶段研究提供了明确的动力[11]